CMAX Clinical Research Pty Ltd
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I Study of NS-079 in Healthy Participants | Healthy Adult Participants | Recruiting | Phase 1 | 2026-09-15 | NCT07669571 | |
| ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 1 | 2026-09-10 | NCT07334080 | |
| Study of BW-50218 in Healthy Participants | Healthy Participants Study | Active, not recruiting | Phase 1 | 2026-09-03 | NCT07401472 | |
| To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Enrolling by invitation | Phase 1 | 2026-08-27 | NCT07505030 | |
| Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | Recruiting | Phase 1 | 2026-08-13 | NCT06934252 | |
| A Study of NHL907 in Healthy Adult Participants | Healthy Adult Participants | Recruiting | Phase 1 | 2026-06-10 | NCT07580924 | |
| A Study of HS-20136-2 in Healthy Participants | Healthy | Not yet recruiting | Phase 1 | 2026-06-01 | NCT07483437 | |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Seizures, Focal, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 1 | 2025-12-29 | NCT06899230 | |
| First-into-human Study of NS-136 in Healthy Subjects | Healthy Subjects | Recruiting | Phase 1 | 2024-11-19 | NCT06345703 |